AI-driven robotics platform reduces drug formulation development time from years to months

人工智能驱动的机器人平台将药物配方开发时间从数年缩短至数月。

SACRAMENTO, Calif.

加利福尼亚州萨克拉门托

,

，

May 19, 2025

2025年5月19日

/PRNewswire/ -- Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today announced the launch of its innovative Cloud Lab platform following the successful closure of an oversubscribed

/PRNewswire/ -- Persist AI，一家在制药配方开发和化学、制造与控制（CMC）领域中以人工智能驱动机器人技术的先驱公司，今天宣布在超额认购成功结束后推出其创新的云端实验室平台。

$12 million

1200万美元

Series A financing round. The new platform allows pharmaceutical companies to develop formulations using Persist AI's state-of-the-art robotic laboratory facilities through a website, dramatically accelerating drug development timelines while using a fraction of the materials required by traditional methods..

A轮融资。新平台允许制药公司通过网站使用Persist AI最先进的机器人实验室设施来开发配方，大幅加快药物开发时间线，同时仅需传统方法所需材料的一小部分。

The funding round was led by Spero Ventures with participation from MBX Capital, Shimadzu Future Innovation Fund managed by Global Brain Corporation, Eli Lilly & Company, SignalFire, Ford Street Capital, Purdue Ventures, Good AI Capital, Cartography Capital, Asymmetry Ventures, and existing investors 2048 Ventures, Innospark, and YCombinator..

本轮融资由Spero Ventures领投，MBX Capital、Global Brain Corporation管理的岛津未来创新基金、礼来公司、SignalFire、Ford Street Capital、Purdue Ventures、Good AI Capital、Cartography Capital、Asymmetry Ventures以及现有投资者2048 Ventures、Innospark和YCombinator参与。

'Every drug that reaches the market depends on an optimal formulation. While the industry has heavily invested in AI and predictive tools across the drug development pipeline, formulation has remained a blind spot—until now.' said

“每一种进入市场的药物都依赖于一个最佳的配方。虽然该行业已经在药物开发管道中大量投资于人工智能和预测工具，但配方一直是一个盲点——直到现在。”

Sara Eshelman

萨拉·埃舍尔曼

, General Partner at Spero Ventures. 'Persist dramatically reduces both the time and cost at every stage of development, ultimately lowering the hurdle for investment in next-generation therapeutics like long-acting injectables.'

Spero Ventures的普通合伙人表示：“Persist大幅减少了开发每个阶段的时间和成本，最终降低了对下一代治疗药物（如长效注射剂）投资的门槛。”

Predict the ideal formulation with Persist's AI models

使用 Persist 的 AI 模型预测理想配方

Persist AI's technology enables pharmaceutical companies to predict formulation recipes and performance using sophisticated AI models and subsequently build and test them using robotic systems. In a recent project with a major pharmaceutical client, Persist AI demonstrated the power of its platform by identifying an optimal long-acting injectable formulation in just two months—a process that traditionally takes a year or longer.

Persist AI的技术使制药公司能够使用复杂的AI模型预测配方和性能，随后通过机器人系统进行构建和测试。在最近与一家大型制药客户合作的项目中，Persist AI仅用两个月就确定了一种最佳的长效注射剂配方，展示了其平台的强大能力——而传统方法通常需要一年或更长时间。

By rapidly building and testing 700 formulations in two months, compared to the industry standard of 10-15 formulations per month, Persist AI accelerates a critical phase in bringing new drugs to market..

通过在两个月内快速构建和测试700种配方，相比行业标准每月10-15种配方，Persist AI加速了将新药推向市场的关键阶段。

'AI is enabling pharma to discover new molecules faster than ever. But a molecule that has poor shelf life cannot become a drug product that sits on a shelf. Our mission is to convert these novel molecules into products, such as tablets and injections that patients can use,' said

“人工智能正在使制药公司发现新分子的速度比以往任何时候都要快。但是，一个具有较差稳定性的分子无法成为可以放在货架上的药品。我们的使命是将这些新颖的分子转化为患者可以使用的产品，例如片剂和注射剂，”他表示。

Karthik Raman

卡提克·拉曼

, CEO of Persist. 'If you can find a new drug molecule, you can predict its formulation and use our robotic platform to build and test it in the real world.'

Persist公司的首席执行官表示：“如果你能找到一种新的药物分子，就可以预测其配方，并使用我们的机器人平台在现实世界中构建和测试它。”

Persist Cloud Lab – A Robotic Lab to Build and Test Formulations Remotely

持久云实验室——一个远程构建和测试配方的机器人实验室

Once the AI models predict a set of formulations, Persist's Cloud Lab enables pharmaceutical scientists to test the formulation by remotely controlling the robotic lab. With a combination of miniaturization and seamless automation of formulation testing instruments, Persist's technology leads to an unprecedented speed advantage in drug development..

一旦人工智能模型预测出一组配方，Persist的云实验室就能让药学科学家通过远程控制机器人实验室来测试配方。通过将微型化和制剂检测仪器的无缝自动化相结合，Persist的技术在药物开发中带来了前所未有的速度优势。

Traditional testing instruments often require large volumes of liquid and significant amounts of formulation material per test. As an example, a standard dissolution testing apparatus requires 1000 mL of liquid and several grams of formulation. In contrast, Persist's miniaturized systems can deliver results with just 1 mL of liquid and a few milligrams of material.

传统测试仪器通常每次测试需要大量液体和大量的配方材料。例如，标准的溶出度测试装置需要1000毫升液体和几克配方。相比之下，Persist的微型化系统只需1毫升液体和几毫克材料即可提供结果。

This breakthrough not only conserves valuable drugs but also enables higher throughput testing..

这一突破不仅节约了宝贵的药物，还实现了更高通量的测试。

'Persist AI has assembled a talented chemistry, engineering, and software team that develops exceptional automated solutions for formulation development workflows,' said

‘Persist AI组建了一支才华横溢的化学、工程和软件团队，为配方开发工作流程提供卓越的自动化解决方案，’

Chris Shelner

克里斯·谢尔纳

, COO of Persist. 'We continue to improve our automation in addition to expanding capacity and workflow scope.'

Persist公司的首席运营官表示：“我们除了扩大产能和工作流程范围外，还不断提升我们的自动化水平。”

Through the newly launched Cloud Lab, pharmaceutical companies worldwide can now remotely build and test formulations on Persist's advanced robotic facilities to develop:

通过新推出的云实验室，全球制药公司现在可以远程在Persist的先进机器人设备上构建和测试配方，以开发：

Long acting injectables

长效注射剂

Tablets and capsules

片剂和胶囊

Topical formulations for cosmetics and pharmaceuticals

化妆品和药品的局部制剂

Injectable formulations

注射制剂

The platform supports a wide range of modalities including peptides, small molecules, antibodies, and anti-sense oligonucleotides, currently serving multiple top 10 pharmaceutical clients and several smaller biotechs developing next-generation treatments for chronic diseases.

该平台支持多种形态，包括肽、小分子、抗体和反义寡核苷酸，目前为多家排名前十的制药客户以及数家开发慢性病下一代疗法的小型生物技术公司提供服务。

Series A Funding to Accelerate Growth and Innovation

A轮融资加速增长与创新

The

The

$12 million

1200万美元

in Series A funding will support several key initiatives. Persist will build a GMP manufacturing system for long acting injectables, in collaboration with Nivagen Pharmaceuticals in

A轮融资将支持几个关键举措。Persist将与Nivagen制药公司合作，建立一个GMP制造系统，用于长效注射剂的生产。

Sacramento, CA.

加利福尼亚州萨克拉门托。

Funds will be used to expand the robotic lab and build comprehensive data sets that train the company's AI models. Additionally, the team will expand the capacity and range of formulations the AI models and robotic lab can predict, build, and test.

资金将用于扩建机器人实验室，并建立训练公司人工智能模型的综合数据集。此外，团队将扩大人工智能模型和机器人实验室可预测、构建和测试的配方的能力和范围。

Persist is actively seeking pharmaceutical partners for co-development of drug products, robotic platforms, and AI training data sets.

Persist正在积极寻求制药合作伙伴，共同开发药物产品、机器人平台和人工智能训练数据集。

To learn more about Persist AI's Cloud Lab platform and request access, visit

要了解更多关于 Persist AI 的 Cloud Lab 平台并请求访问，请访问

https://www.persist-ai.com

https://www.persist-ai.com

. Pharmaceutical companies interested in partnership opportunities are encouraged to contact

鼓励有兴趣合作的制药公司联系

Karthik Raman

卡提克·拉曼

via his email below or through the website.

通过以下电子邮件或通过网站。

About Persist AI

关于Persist AI

Persist AI is revolutionizing pharmaceutical development through AI-driven robotics for formulation development and CMC. By combining predictive AI models with automated robotic systems, Persist AI enables pharmaceutical companies to develop drug formulations in a fraction of the time and cost of traditional approaches.

Persist AI 正在通过用于配方开发和CMC的AI驱动机器人技术彻底改变制药开发。通过将预测性AI模型与自动化机器人系统相结合，Persist AI使制药公司能够以传统方法所需时间的一小部分和成本开发药物配方。

The company works across multiple modalities and formulation types to accelerate bringing novel therapeutics to patients. Persist AI is a Y Combinator-backed company, having graduated from the prestigious startup accelerator in 2023..

该公司跨多种方式和配方类型开展工作，以加速将新型疗法带给患者。Persist AI是一家获得Y Combinator支持的公司，于2023年从这家知名创业加速器毕业。

About the Leadership Team

关于领导团队

Karthik Raman

卡提克·拉曼

, CEO and Co-founder of Persist, brings extensive expertise in formulation development. Prior to founding Persist, Raman was part of the automation team at Zymergen, developing the next generation robotic factory for synthetic biology. Co-founder

Persist公司的首席执行官兼联合创始人拉曼在配方开发方面拥有丰富的专业知识。在创立Persist之前，拉曼曾在Zymergen的自动化团队中工作，参与开发了用于合成生物学的新一代机器人化工厂。联合创始人

Christopher Shelner

克里斯托弗·谢尔纳

serves as Chief Operating Officer, with significant expertise in automation design, operations, and deployment from his work at industry leaders including Northrop Grumman and Apple.

担任首席运营官，凭借在诺斯罗普·格鲁曼公司和苹果等业界领先企业的工作经验，在自动化设计、运营和部署方面拥有深厚的专业知识。

SOURCE Persist AI Formulations

来源：Persist AI 配方

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用